Research Article
Incidence and Predictors of Antiretroviral Treatment Modification in HIV-Infected Adults: A Brazilian Historical Cohort from 2001 to 2010
Table 1
Baseline characteristics of the HIV/AIDS patients from the historical cohort, Belo Horizonte, Brazil.
| | Variables | Global () | ART modification
() | | (%) | (%) | |
| | Sociodemographic | | | | | Age at ART beginning (years) | | | 0.207 | | ≤35 | 114 (48.3) | 57 (50.0) | | | >35 | 122 (51.7) | 51 (41.8) | | | Sex | | | 0.461 | | Male | 148 (62.7) | 65 (43.9) | | | Female | 88 (37.3) | 43 (48.9) | | | Marital status | | | 0.669 | | Single/divorced/widower | 144 (64.9) | 64 (44.4) | | | Marriage/stable union | 78 (35.1) | 37 (47.4) | | | City of residence | | | 0.737 | | Belo Horizonte | 149 (63.7) | 70 (47.0) | | | Metropolitan area/countryside | 85 (36.3) | 38 (44.7) | | | Occupation category | | | 0.336 | | Formal job | 155 (70.4) | 74 (47.7) | | | Unemployment/retired/housemaid | 64 (29.2) | 26 (40.6) | | | Related to health assistance | | | | | HIV/AIDS referral center | | | 0.793 | | Center 1/Center 2 | 41 (17.4) | 18 (43.9) | | | Center 3 | 195 (82.6) | 90 (45.2) | | | Average medical visits/year | | | 0.433 | | ≤4 | 191 (82.3) | 85 (44.5) | | | >4 | 41 (17.7) | 21 (51.2) | | | Time between HIV diagnosis and initial ART (days) | | | 0.824 | | ≤90 | 105 (47.3) | 46 (43.8) | | | >90 | 117 (52.7) | 53 (45.3) | | | Hospitalization | | | 0.440 | | No | 195 (82.6) | 87 (44.6) | | | Yes | 41 (17.4) | 21 (51.2) | | | Clinical and laboratorial data | | | | | Initial CD4+ T-lymphocyte (cells/mm3) | | | 0.258 | | <200 | 119 (59.2) | 59 (49.6) | | | 200–350 | 55 (27.4) | 23 (41.8) | | | >350 | 27 (13.4) | 9 (33.3) | | | Viral load (copies/mL) | | | 0.516 | | ≤100.000 | 105 (65.6) | 44 (41.9) | | | >100.000 | 55 (34.4) | 26 (47.3) | | | AIDS-defining illness | | | 0.145 | | No | 94 (44.3) | 36 (38.3) | | | Yes | 118 (55.7) | 57 (48.3) | | | First classes of ART regimen prescribed | | | <0.001 | | 2 NRTI + NNRTI | 135 (57.2) | 43 (32.6) | | | 2 NRTI + PI | 101 (42.8) | 65 (64.3) | | | Most commonly first ART combination | | | <0.001 | | ZDV + 3TC + EFV | 83 (35.2) | 20 (24.1) | | | ZDV + 3TC + NFV | 47 (19.9) | 28 (60.0) | | | ZDV + 3TC + NVP | 37 (15.7) | 15 (40.5) | | | ZDV + 3TC + IDV | 17 (7.2) | 10 (58.2) | | | ZDV + ddI + NFV | 10 (4.2) | 7 (70.0) | | | ZDV + ddI + NVP | 8 (3.4) | 4 (50.0) | | | ZDV + 3TC + IDV/r | 6 (2.5) | 5 (83.3) | | | d4T + 3TC + EFV | 4 (1.7) | 2 (50.0) | | | d4T + 3TC + NFV | 4 (1.7) | 2 (50.0) | | | | 20 (8.5) | 15 (75.0) | | | Total | 236 | 108 | |
|
|
3TC: lamivudine, ART: antiretroviral therapy, d4T: stavudine, ddI: didanosine, EFV: efavirenz, IDV/r: indinavir/ritonavir, NFV: nelfinavir, NRTI: nucleoside reverse transcriptase inhibitor, and NNRTI: nonnucleoside reverse transcriptase inhibitor. NVP: nevirapine, PI: protease inhibitors, and ZDV: zidovudine.
values were not shown.
chi-square test.
include ART combinations containing lopinavir, lopinavir/ritonavir, amprenavir, atazanavir, saquinavir, and different combinations of the antiretrovirals presented.
|
